日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

奈拉替尼治疗ERBB2突变型肺腺癌的疗效:两项国际II期研究的结果

Li, Bob T; Gandhi, Leena; Ravichandran, Vignesh; Besse, Benjamin; Mazières, Julien; Shapiro, Geoffrey I; Boni, Valentina; Waqar, Saiama N; Park, Haeseong; Quinn, David I; Martinez, Alejandro; Stemmer, Salomon M; Cortot, Alexis B; Barlesi, Fabrice; Quoix, Elisabeth; Burkard, Mark E; Selcuklu, S Duygu; Hunt, Casey; Donoghue, Mark T A; Kris, Mark G; Bebchuk, Judith; Eli, Lisa D; McCulloch, Leanne; Solit, David B; Jänne, Pasi A

Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer.

去势抵抗性前列腺癌患者接受恩扎卢胺单药治疗或联合镭-223治疗期间的免疫调节

Zang Peter D, Da Silva Diane M, Liu Zhang-Xu, Kandukuri Shivani, Tsao-Wei Denice, D'Souza Anishka, Kast W Martin, Pal Sumanta K, Kefauver Cheryl, Juanqueira Maribel, Yang Lixin, Quinn David I, Dorff Tanya B

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma

一项 I/IB 期、开放标签、剂量探索研究,旨在评估帕博利珠单抗联合伏立诺他治疗晚期前列腺癌、肾癌或尿路上皮癌患者的安全性、药效学和疗效。

Pili, Roberto; Quinn, David I; Adra, Nabil; Logan, Theodore; Colligan, Sean; Burney, Heather N; Hahn, Noah M

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

循环肿瘤细胞计数与转移性激素敏感性前列腺癌患者的总生存期

Goldkorn, Amir; Tangen, Catherine; Plets, Melissa; Bsteh, Daniel; Xu, Tong; Pinski, Jacek K; Ingles, Sue; Triche, Timothy Junius; MacVicar, Gary R; Vaena, Daniel A; Crispino, Anthony W; McConkey, David James; Lara, Primo N Jr; Hussain, Maha H A; Quinn, David I; Dorff, Tanya B; Lerner, Seth Paul; Thompson, Ian Jr; Agarwal, Neeraj

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

转移性激素敏感性前列腺癌患者治疗后3个月和7个月的前列腺特异性抗原水平作为总生存期的预后标志物:来自SWOG S1216研究的结果,这是一项比较雄激素剥夺疗法联合奥特罗内或比卡鲁胺的3期随机试验。

Parikh, Mamta; Tangen, Catherine; Hussain, Maha H A; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J; George, Saby; Zibelman, Matthew R; Cheng, Heather H; Maughan, Benjamin L; Zhang, Jingsong; Pachynski, Russell K; Bryce, Alan H; Lin, Daniel W; Quinn, David I; Lerner, Seth P; Thompson, Ian M; Dorff, Tanya B; Lara, Primo N; Agarwal, Neeraj

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

骨代谢标志物与骨转移性激素敏感性前列腺癌 (HSPC) 患者总生存期的关系:SWOG S1216 的亚组分析,一项关于雄激素剥夺联合或不联合奥特罗内治疗的 III 期临床试验

Lara, Primo N Jr; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I; LeBlanc, Michael; Thompson, Ian; Agarwal, Neeraj

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

帕博利珠单抗联合可溶性EphB4-白蛋白治疗HPV阴性EphrinB2阳性头颈部鳞状细胞癌的疗效得到改善

Jackovich, Alexandra; Gitlitz, Barbara J; Tiu-Lim, Justin Wayne Wong; Duddalwar, Vinay; King, Kevin George; El-Khoueiry, Anthony B; Thomas, Jacob Stephen; Tsao-Wei, Denice; Quinn, David I; Gill, Parkash S; Nieva, Jorge J

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

骨生物标志物与激素敏感性前列腺癌患者的后续生存率:来自SWOG S1216 III期临床试验的结果,该试验比较了使用或不使用奥特罗内尔的雄激素剥夺疗法。

Lara, Primo N Jr; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I; LeBlanc, Michael; Vogelzang, Nicholas J; Thompson, Ian; Agarwal, Neeraj

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial

既往细胞减灭性肾切除术对接受阿维鲁单抗联合阿昔替尼或舒尼替尼治疗的同步转移性肾细胞癌患者疗效的影响:JAVELIN Renal 101 III期试验的事后分析

Grimm, Marc-Oliver; Oya, Mototsugu; Choueiri, Toni K; Motzer, Robert J; Schmidinger, Manuela; Quinn, David I; Gravis-Mescam, Gwenaelle; Verzoni, Elena; Van den Eertwegh, Alfonsus J M; di Pietro, Alessandra; Mariani, Mariangela; Wang, Jing; Thomaidou, Despina; Albiges, Laurence

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

FORT-1:一项针对基于FGFR1/3 mRNA表达选择的局部晚期或转移性尿路上皮癌患者的罗加替尼与化疗的II/III期研究

Sternberg, Cora N; Petrylak, Daniel P; Bellmunt, Joaquim; Nishiyama, Hiroyuki; Necchi, Andrea; Gurney, Howard; Lee, Jae-Lyun; van der Heijden, Michiel S; Rosenbaum, Eli; Penel, Nicolas; Pang, See-Tong; Li, Jian-Ri; García Del Muro, Xavier; Joly, Florence; Pápai, Zsuzsanna; Bao, Weichao; Ellinghaus, Peter; Lu, Chengxing; Sierecki, Mitchell; Coppieters, Sabine; Nakajima, Keiko; Ishida, Tatiane Cristine; Quinn, David I